Abstract: Glucose dendrimers synthesized using a hypercore and glucose monosaccharide-based branching units significantly enhances accumulation in neurons in the brain and in retina when administered in vivo, as compared with dendrimers without glucose monosaccharide-based branching units such as PAMAM. Compositions of glucose dendrimers conjugated with one or more therapeutic, prophylactic or diagnostic agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and/or ameliorating diseases or disorders associated with diseased neurons in the eye or the brain. Methods of treating a human subject having or at risk of a neurological disease or disorder are provided.

Abstract: A dendrimer that includes: (a) a central core; and (b)(i) at least one 2-deoxyglucose-surfaced branching units conjugated to the central core; or (b)(ii) at least one trehalose-surfaced branching units conjugated to the central core; or (b)(iii) at least one 2-deoxyglucose-surfaced branching units conjugated to the central core and at least one trehalose-surfaced branching units conjugated to the central core.

Abstract: The present invention relates to the dosage and administration of anti-BCMA x anti-CD3 binding molecules for the treatment of BCMA positive neoplasms. More specifically, the present invention relates to a protein comprising a first domain which binds to BCMA, a second domain which binds to CD3 and a third domain which enhances the half-life of the protein, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the protein is administered at a specified dose regimen in at least one cycle. Moreover, the invention relates to a method for the treatment or amelioration of a BCMA positive neoplasm comprising administering a specified dose regimen of such binding molecule, to methods for administering therapeutic doses of such binding molecules and to the use of such binding molecules for the manufacture of a medicament for the treatment or amelioration of a BCMA positive neoplasm.

Abstract: Conjugation of dendrimer molecules with one or more carbohydrate moieties significantly enhances targeting of tumor-associated macrophages (TAMs) and microglia by increasing brain penetration and cellular internalization, as compared with dendrimers without modification with carbohydrate molecules. Compositions of dendrimers conjugated with carbohydrate moieties, particularly glucose and/or glucosamine, and one or more active agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and/or ameliorating brain and/or CNS tumors. Methods of treating a human subject having or at risk of brain and/or CNS tumors are provided.

Abstract: Compositions of dendrimers conjugated with one or more glutamine antagonist(s) that inhibit glutamine metabolism, preferably in activated microglia, and methods of use thereof for treating, alleviating, and/or preventing one or more neurological, oncological, and/or immune disorders associated with pathogenic or dysregulated glutamine-dependent pathways and/or glutamate transmission, have been developed. Dendrimers conjugated with one or more glutamine antagonists effectively inhibit the activity of glutaminase without any systemic toxicity. Dendrimers conjugated with one or more glutamine antagonists accumulate in activated microglia associated with the injured or diseased cells and tissues.

Abstract: Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.

Abstract: Compositions of dendrimers conjugated with galactose and one or more active agents to prevent, treat or diagnose a liver injury, liver disease or liver disorder in a subject in need thereof, and methods of use thereof, have been developed. Preferably, the therapeutic agents are one or more anti-inflammatory agents. The compositions are particularly suited for treating and/or ameliorating one or more symptoms of non-alcoholic steatohepatitis and severe acetaminophen poisoning. Methods of treating a human subject having or at risk of non-alcoholic steatohepatitis and severe acetaminophen poisoning are provided.

Abstract: Compositions of dendrimers conjugated with one or more therapeutic agents that decrease exosome secretion and methods of use thereof for treating, alleviating, and/or preventing one or more symptoms associated with one or more neurological disease or disorders, cancer, inflammatory diseases, bacterial and viral infections, and other disorders have been developed. Preferably, the therapeutic agents are one or more agents that inhibit or reduce activity and/or quantity of neutral sphingomyelinase 2 (nSMase2) such as small molecule inhibitors of nSMase2. Compositions are particularly suited for reducing A? plaque formation, reducing tau propagation, improving cognition, or combinations thereof in a subject with psychiatric and neurological disorders. Compositions are also suited for treating, alleviating, and/or preventing one or more symptoms associated with cancer, bacterial and viral infections, and inflammatory diseases.

Abstract: Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. ˜120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.

Abstract: The present invention provides a device and method for filtering impulsive noise and channel switching noise at ADC in an ECG device with multiplexed ESCs. The filtering is based on an implementation of Burst Sampling technique also a method for correcting errors in derived leads caused by time delays due to sequential sampling of different ECG signals is also provided. Real time digital FIR filters are used for removing other types of noise in ECG signals. The ECG device is compact and light weight and includes features of self calibration, clip detection and drawing of power from USB port of a PC, batteries or an external power source. The ECG monitoring device of the present invention measures real time ECG signals with automated data recording, data storage and retrieval, data transmission/transfer to an external system, along with parameter extraction for ECG analysis in an efficient manner for quick and reliable ECG measurement, in an extremely cost effective manner.

Abstract: The present invention provides a device and method for filtering impulsive noise and channel switching noise at ADC in an ECG device with multiplexed ESCs. The filtering is based on an implementation of Burst Sampling technique also a method for correcting errors in derived leads caused by time delays due to sequential sampling of different ECG signals is also provided. Real time digital FIR filters are used for removing other types of noise in ECG signals. The ECG device is compact and light weight and includes features of self calibration, clip detection and drawing of power from USB port of a PC, batteries or an external power source. The ECG monitoring device of the present invention measures real time ECG signals with automated data recording, data storage and retrieval, data transmission/transfer to an external system, along with parameter extraction for ECG analysis in an efficient manner for quick and reliable ECG measurement, in an extremely cost effective manner.